Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole

Coyne, C.P.; Jones, Toni; Bear, Ryan

doi:10.17303/jcrto.2014.203

Cited by 2 publications

(3 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro, MBZ was also able to stimulate antitumoral immune response by polarization of macrophages towards M1 tumor-suppressive phenotype [66,67,68]. Mebendazole demonstrated synergy with different chemotherapeutic agents, allowing to overcome chemoresistance to cisplatin [56], TMZ [53], and anti-HER2 conjugates with anthracycline or gemcitabine [52]. Mebendazole also exhibited potent activity as a radiosensitizer by enhancing radiation-induced DNA damage in cancer cells [50,51,55].…”

Section: Discussionmentioning

confidence: 99%

“…In vivo, MBZ was evaluated on SUM159PT mice xenografts: MBZ alone resulted in modest delay of tumor growth, while the effect of a single fraction of radiotherapy (10 Gy) was evident and was enhanced by the addition of MBZ. Coyne et al analyzed the effect of MBZ against HER2+ human mammary adenocarcinoma SKBr-3 [52]: cytotoxicity was dose- and time-dependent, reporting an IC 50 of about 0.35 and 0.25 μM after 96 or 182 h. Mebendazole also had a synergistic antineoplastic effect with immunochemotherapeutics obtained by covalent binding of anti-HER2 and anthracyclines or gemcitabine. Kipper et al [53] tested MBZ, TMZ, and vinblastine (VBL) in vitro on several glioma cell lines at concentrations in the range of those measured in the plasma of patients treated with the usual therapeutic dose.…”

Section: Preclinical Evidence Of Anticancer Activitymentioning

confidence: 99%

See 1 more Smart Citation

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

Guerini

Triggiani

Maddalo

et al. 2019

Cancers

107

View full text Add to dashboard Cite

Anticancer treatment efficacy is limited by the development of refractory tumor cells characterized by increased expression and activity of mechanisms promoting survival, proliferation, and metastatic spread. The present review summarizes the current literature regarding the use of the anthelmintic mebendazole (MBZ) as a repurposed drug in oncology with a focus on cells resistant to approved therapies, including so called “cancer stem cells”. Mebendazole meets many of the characteristics desirable for a repurposed drug: good and proven toxicity profile, pharmacokinetics allowing to reach therapeutic concentrations at disease site, ease of administration and low price. Several in vitro studies suggest that MBZ inhibits a wide range of factors involved in tumor progression such as tubulin polymerization, angiogenesis, pro-survival pathways, matrix metalloproteinases, and multi-drug resistance protein transporters. Mebendazole not only exhibits direct cytotoxic activity, but also synergizes with ionizing radiations and different chemotherapeutic agents and stimulates antitumoral immune response. In vivo, MBZ treatment as a single agent or in combination with chemotherapy led to the reduction or complete arrest of tumor growth, marked decrease of metastatic spread, and improvement of survival. Further investigations are warranted to confirm the clinical anti-neoplastic activity of MBZ and its safety in combination with other drugs in a clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Preclinical Evidence Of Anticancer Activitymentioning

confidence: 99%

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

Guerini

Triggiani

Maddalo

et al. 2019

Cancers

107

View full text Add to dashboard Cite

show abstract

“…MBZ caused complete remission of the metastases in the lungs and lymph nodes, with no adverse effect to patients [37,38]. Furthermore, MZ showed anticancer activity against gastric cancer (GC) [39], brain tumor [40], glioblastoma [41], medulloblastoma [42,43], prostate cancer [44], bile duct cancer [45], pancreatic cancer [46], head and neck cancer [47], breast cancer [48], and melanoma [49][50][51]. MZ has been tested preclinically as a replacement for vincristine, a drug that has dose-limiting toxicity in the treatment of brain tumors [102].…”

Section: Mzmentioning

confidence: 99%

Double Repositioning: Veterinary Antiparasitic to Human Anticancer

Sultana

Jan

Lee

2022

IJMS

View full text Add to dashboard Cite

Drug repositioning, the approach of discovering different uses for existing drugs, has gained enormous popularity in recent years in the anticancer drug discovery field due to the increasing demand for anticancer drugs. Additionally, the repurposing of veterinary antiparasitic drugs for the treatment of cancer is gaining traction, as supported by existing literature. A prominent example is the proposal to implement the use of veterinary antiparasitics such as benzimidazole carbamates and halogenated salicylanilides as novel anticancer drugs. These agents have revealed pronounced anti-tumor activities and gained special attention for “double repositioning”, as they are repurposed for different species and diseases simultaneously, acting via different mechanisms depending on their target. As anticancer agents, these compounds employ several mechanisms, including the inhibition of oncogenic signal transduction pathways of mitochondrial respiration and the inhibition of cellular stress responses. In this review, we summarize and provide valuable information about the experimental, preclinical, and clinical trials of veterinary antiparasitic drugs available for the treatment of various cancers in humans. This review suggests the possibility of new treatment options that could improve the quality of life and outcomes for cancer patients in comparison to the currently used treatments.

show abstract

Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole

Cited by 2 publications

References 164 publications

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

Double Repositioning: Veterinary Antiparasitic to Human Anticancer

Contact Info

Product

Resources

About